摘要
目的考察达格列净与利拉鲁肽对超重2型糖尿病患者体脂成分变化影响。方法选取2020年1~12月于我院诊治的超重2型糖尿病患者100例,随机数字法分为利拉鲁肽组(Lir组)和达格列净组(Dap组),每组50例,均连续治疗3个月,比较两组患者临床治疗有效率、治疗前后血糖相关指标及体脂成分指标(体脂肪率、内脏脂肪指数及四肢皮下脂肪率)。结果相比于Dap组,Lir组的临床治疗有效率显著升高,差异具有统计学意义(P<0.05);Lir组和Dap组治疗前在血糖相关指标及体脂成分上相比,差异无统计学意义(P>0.05);相比于Dap组,Lir组治疗后HbA1c、FPG和2hPG均显著降低,差异具有统计学意义(P<0.05);相比于Dap组,Lir组治疗后体脂肪率、内脏脂肪指数及四肢皮下脂肪率均显著降低,差异具有统计学意义(P<0.05)。结论相比于达格列净,利拉鲁肽能够显著降低超重2型糖尿病患者的体脂成分及血糖相关指标,临床治疗效果较好。
Objective To investigate the comparative study of the effect of Dapagliflozin and Liraglutide on body fat composition in overweight patients with type 2 diabetes mellitus.Methods 100 cases overweight patients with type 2 diabetes mellitus diagnosed and treated in our hospital from January to December 2020,according to the random number divided into Liraglutide group(Lir group)and Dapagliflozin group(Dap group),with 50 patients in each group.All patients were treated continuously for 3 months.Compared with the clinical effective rate,blood glucose related indexes and body fat composition indexes(body fat percentage,visceral fat index and subcutaneous fat percentage of limbs)before and after treatment between the two groups.Results Compared with the Dap group,the clinical effective rate of Lir group was significantly increased,and the difference was statistically significant(P<0.05);Before treatment,compared with the blood glucose related indexes and body fat composition of the Lir group and Dap group,and the difference was not statistically significant(P>0.05);Compared with Dap group,the HbA1c,FPG and 2hPG in Lir group were significantly decreased after treatment,the difference was statistically significant(P<0.05);Compared with Dap group,the body fat percentage,visceral fat index and subcutaneous fat percentage of limbs in Lir group were significantly decreased after treatment,the difference was statistically significant(P<0.05).Conclusion Compared with Dapagliflozin,Liraglutide can significantly reduce the body fat composition and blood glucose related indexes in overweight patients with type 2 diabetes mellitus,and the clinical treatment effect is better.
作者
钱程
王丽云
马铁梁
王铮
张菀姣
陆婷
QIAN Cheng;WANG Liyun;MA Tieliang;WANG Zheng;ZHANG Wanjiao;LU Ting(Endocrine Department,Yixing people’s Hospital,Yixing,Jiangsu 214200;Central Laboratory,Yixing people’s Hospital,Yixing,Jiangsu 214200)
出处
《智慧健康》
2022年第2期127-129,共3页
Smart Healthcare
关键词
2型糖尿病
达格列净
超重
利拉鲁肽
体脂
Type 2 diabetes mellitus
Dapagliflozin
Overweight
Liraglutide
Body fat
作者简介
钱程(1985-),女,汉族,硕士,副主任医师,研究方向:内分泌学;通信作者:王丽云(1971-),女,汉族,硕士,主任医师,研究方向:内分泌学。
